In a study by Evans et al., SBRT to oligometastatic lesions of prostate cancer with various dose–fractionation schedules with a daily dose of 10 Gy or higher increased tumor-reactive CD8+ T cells, defined by the expression of CD11a in the peripheral blood [42]. The gene discussed is CD8A; the disease is prostate cancer.